Micreos spins off to focus on innovative pharmaceuticals to transform patient care in the treatment of chronic and acute bacterial infections.

Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome.  This has the potential to play a significant role in addressing the impending antimicrobial resistance (AMR) issues.

The pharmaceutical business, that carries the Micreos name, is now an independent company that can focus wholeheartedly on engineered endolysin and engineered phage-based antimicrobials, initially focusing on Staphylococcus aureus (S. aureus) in oncology, dermatology, and bloodstream infections.

Matt Regan, CEO of Micreos, says: “The heritage of Micreos has enabled us to build a very solid pharmaceutical business model centered around a highly structured drug discovery and drug development approach focusing on three therapeutic areas – namely oncology, dermatology, and bloodstream infections. The impact of harmful bacteria on disease progression in chronic and acute settings and global concerns around antibiotic resistance leaves patients and clinicians with increasingly limited options. Our Micreos technology provides a potential novel approach to target both these issues in a highly sustainable way. Now it’s time to forge our own path forward, together with our investors and our scientific partners. It’s full steam ahead from here on.”

In parallel with the spin-off, a new leadership team has been assembled, bringing in decades of experience from the pharmaceutical industry. You can read more about the Micreos leadership team here